Medication Summary
Drug therapy for pityriasis rosea primarily consists of symptomatic treatment of pruritus. Oral antihistamines and topical corticosteroids can be used as needed. For patients in whom superficial tinea infection is a concern or possibility, topical antifungal therapy can be used.
Chuh et al (2007) assessed the efficacy of interventions for pityriasis rosea.[8] They found that evidence for efficacy for most treatments for pityriasis rosea is inadequate. Erythromycin has been reported as effective in the treatment of pityriasis rosea. However, in a placebo-controlled study conducted by Rasi et al (2008), oral erythromycin was not found to confer a significant benefit in 184 patients with pityriasis rosea.[9]
Management of pityriasis rosea in patients with evidence of group A streptococcal infection may be warranted. The possible risk of scarlet fever and poststreptococcal sequelae should be considered.[10]
Antihistamines
Class Summary
Consider oral antihistamine therapy in patients with pruritus. These agents may control itching by blocking effects of endogenously released histamine.
Hydroxyzine (Atarax, Vistaril)
Effective antipruritic in the treatment of pityriasis rosea. Antagonizes H1 receptors in periphery.
Diphenhydramine (Benadryl, Benylin)
Very safe oral antihistamine. Can be used safely in pregnancy. For symptomatic relief of symptoms caused by release of histamine in allergic reactions. Very effective in controlling pruritus.
Amer A, Fischer H, Li X. The natural history of pityriasis rosea in black American children: how correct is the "classic" description?. Arch Pediatr Adolesc Med. May 2007;161(5):503-6. [Medline].
Robati RM, Toossi P. Plantar herald patch in pityriasis rosea. Clin Exp Dermatol. Mar 2009;34(2):269-70. [Medline].
Ang CC, Tay YK. Blaschkoid pityriasis rosea. J Am Acad Dermatol. Nov 2009;61(5):906-8. [Medline].
Zawar V, Godse K. Annular groin eruptions: pityriasis rosea of vidal. Int J Dermatol. Feb 2011;50(2):195-7. [Medline].
Kempf W, Adams V, Kleinhans M, et al. Pityriasis rosea is not associated with human herpesvirus 7. Arch Dermatol. Sep 1999;135(9):1070-2. [Medline].
González LM, Allen R, Janniger CK, et al. Pityriasis rosea: an important papulosquamous disorder. Int J Dermatol. Sep 2005;44(9):757-64. [Medline].
Rajpara SN, Ormerod AD, Gallaway L. Adalimumab-induced pityriasis rosea. J Eur Acad Dermatol Venereol. Oct 2007;21(9):1294-6. [Medline].
Chuh AA, Dofitas BL, Comisel GG, et al. Interventions for pityriasis rosea. Cochrane Database Syst Rev. Apr 18 2007;CD005068. [Medline].
Rasi A, Tajziehchi L, Savabi-Nasab S. Oral erythromycin is ineffective in the treatment of pityriasis rosea. J Drugs Dermatol. Jan 2008;7(1):35-8. [Medline].
Krishnamurthy K, Walker A, Gropper CA, Hoffman C. To treat or not to treat? Management of guttate psoriasis and pityriasis rosea in patients with evidence of group A Streptococcal infection. J Drugs Dermatol. Mar 2010;9(3):241-50. [Medline].
Chuang TY, Ilstrup DM, Perry HO, et al. Pityriasis rosea in Rochester, Minnesota, 1969 to 1978. J Am Acad Dermatol. Jul 1982;7(1):80-9. [Medline].
Cohen EL. Pityriasis rosea. Br J Dermatol. Oct 1967;79(10):533-7. [Medline].
Harman M, Aytekin S, Akdeniz S, et al. An epidemiological study of pityriasis rosea in the Eastern Anatolia. Eur J Epidemiol. Jul 1998;14(5):495-7. [Medline].
Hartley AH. Pityriasis rosea. Pediatr Rev. Aug 1999;20(8):266-9, quiz 270. [Medline].
Parsons JM. Management of toxic epidermal necrolysis. Cutis. Oct 1985;36(4):305-7, 310-1. [Medline].
Tay YK, Goh CL. One-year review of pityriasis rosea at the National Skin Centre, Singapore. Ann Acad Med Singapore. Nov 1999;28(6):829-31. [Medline].
Wyndham M. Pityriasis. Practitioner. Jun 1997;241(1575):358. [Medline].

